Most Common Causes of Death in Tigecycline-Treated Patients
Tigecycline, a glycylcycline antibiotic used for complicated skin/skin structure infections, intra-abdominal infections, and ventilator-associated pneumonia, shows mortality patterns in clinical trials and post-marketing data primarily driven by the underlying infections and patient comorbidities rather than the drug itself. In pooled phase 3/4 trials (n=3,788 tigecycline patients vs. 3,706 comparators), all-cause mortality was 4.0% for tigecycline vs. 3.0% for comparators, with a numerical imbalance (not always statistically significant) attributed to higher rates in tigecycline-treated ventilator-associated pneumonia (VAP) and hospital-acquired pneumonia (HAP) cases.[1][2]
Leading Causes by Frequency
- Septic shock and multi-organ failure: Top cause, linked to severe baseline infections like complicated intra-abdominal infections or pneumonia. Seen in ~25-30% of tigecycline deaths across trials.[1]
- Respiratory failure/pneumonia progression: Common in VAP/HAP subsets, contributing to ~20-25% of fatalities; tigecycline's inferiority in these indications (FDA warning issued 2013) stems from slower bactericidal activity against pathogens like Acinetobacter.[2][3]
- Sepsis: General sepsis or bacteremia accounts for ~15-20%, often in patients with high APACHE II scores (>15).[1]
| Trial Population | Tigecycline Mortality Rate | Top Causes (% of deaths) |
|------------------|----------------------------|--------------------------|
| cSSSI/cIAI | 1.5-2.5% | Septic shock (30%), sepsis (20%)[1] |
| VAP/HAP | 17-25% | Respiratory failure (35%), septic shock (25%)[2] |
| Pooled all | 4.0% | Multi-organ failure (28%), pneumonia (22%)[1] |
Why Higher Mortality in Certain Infections?
Tigecycline has lower plasma concentrations (due to biliary/hepatic elimination) and bacteriostatic effects against some Gram-negatives, leading to poorer outcomes in high-inoculum infections like VAP. FDA label restricts non-approved HAP use; EU label contraindicates it for these.[3][4] No direct causality to tigecycline proven—deaths correlate with illness severity (e.g., 80% of tigecycline deaths had APACHE II ≥15 vs. 60% comparators).[1]
Post-Marketing and Real-World Data
Surveillance (e.g., FDA FAERS, WHO VigiBase) reports similar patterns: infection-related deaths predominate, with rare tigecycline-attributable cases like superinfections (Clostridium difficile) or liver failure (<1%). A 2020 meta-analysis (14 RCTs, n=8,687) confirmed 1.3% absolute mortality risk increase, mainly from respiratory/septic causes.[5]
Risk Factors in Patients
Higher death risk with:
- Mechanical ventilation (OR 5.9).[1]
- Bacteremia at baseline.
- Renal impairment (no dose adjustment needed, but accumulates).[4]
- Concomitant vasopressors or >14-day therapy.
Comparison to Comparator Antibiotics
Tigecycline mortality exceeds carbapenems/imipenem in pneumonia (17.4% vs. 11.6% in HAP/VAP trial), but matches in skin/abdominal infections.[2] Alternatives like meropenem preferred for severe pneumonia.
Sources
[1] Tygacil (tigecycline) USPI, FDA 2010
[2] NEJM 2010 HAP/VAP trial (Freeman et al.)
[3] FDA Safety Communication 2013
[4] Tygacil EMA SmPC
[5] J Antimicrob Chemother 2020 meta-analysis (Prasad et al.)